Effects of beta2-agonists on resident and infiltrating inflammatory cells.
beta(2)-adrenergic receptors are present on inflammatory cells such as mast cells, monocytes, eosinophils, T-lymphocytes, and neutrophils implicated in the pathophysiology of respiratory disease. Short-acting beta(2)-agonists (eg, albuterol) and long-acting beta(2)-agonists (eg, salmeterol, formoterol) inhibit cell activation, inflammatory mediator release, and cell recruitment and survival mechanisms in vitro, with evidence of cellular specificity in response. In some cases, these effects can be observed in vivo, particularly with the long-acting agents. Reductions in inflammatory cell numbers, activation status in airway tissue, and inflammatory markers in sputum, bronchoalveolar lavage fluid, and blood have been reported after administration of clinical doses of salmeterol and formoterol. The inflammatory cell inhibitory activity of beta(2)-agonists is increased in the presence of corticosteroids, resulting in additive and/or synergistic effects on mediator release, adhesion molecule expression, and cellular proliferation. In vivo, the combination of long-acting beta(2)-agonist and corticosteroid exhibits an anti-inflammatory effect greater than that of the agonist alone, as well as a reduction in airway vascularity, a component of remodeling, that corticosteroids alone cannot produce.
Johnson
Malcolm
M
GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom.
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D001249:Asthma / Q000188:drug therapy / Q000276:immunology; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008168:Lung / Q000187:drug effects* / Q000276:immunology; D008407:Mast Cells / Q000187:drug effects*
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D005938:Glucocorticoids